Sodium Ibandronate Injection (Sodium Ibandronate Hemihydrate)
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Samsung Pharmaceutical Co., Ltd.
MFDS item code 201604442 · Notified 2016.07.19 · Insurance code 642306871
Treatment of osteoporosis in postmenopausal women
This medication is used to treat osteoporosis that may occur in postmenopausal women. Osteoporosis is a condition characterized by weakened bones and an increased risk of fractures, which occurs commonly in women after menopause. This drug helps to increase bone density and reduce the risk of fractures, thereby maintaining a healthy skeletal structure. Therefore, it is effective for the prevention and treatment of osteoporosis in postmenopausal women.
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and resume regular administration at 3-month intervals from then on. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or greater. Because clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this medicine is not recommended. Older adults No dose adjustment is necessary.
Efficacy and safety in children aged 18 years and younger have not been studied.
This medication must be administered intravenously, and caution is necessary to avoid injection near the arteries or veins, as this may cause tissue damage. It should not be administered to patients with an allergy to this drug or its ingredients or to those with untreated hypocalcemia. Using this medication may cause gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation. Muscle pain, joint pain, headache, rash, and fatigue have also been reported, with most symptoms being mild to moderate. Upon initial administration, symptoms similar to influenza such as joint pain, muscle pain, fever, chills, fatigue, nausea, loss of appetite, and bone pain may occur, but most resolve naturally in a short period. Some patients receiving this medication may develop osteonecrosis of the jaw, so oral examination and appropriate dental treatment are recommended before administration. During treatment, it is advisable to avoid unnecessary dental work and consult a specialist if osteonecrosis is suspected. This medication may temporarily lower calcium levels, so treatment for hypocalcemia or bone and mineral metabolism disorders must be completed before administration, and it is important to ensure adequate intake of calcium and vitamin D. Patients with chronic kidney disease or those taking medications that may affect the kidneys require regular examinations and tests. Patients receiving this medication may experience severe pain in muscles, joints, and bones, and if such symptoms occur, immediate consultation with healthcare professionals is necessary. Long-term use may lead to atypical fractures of the femur or other bones, so immediate evaluation is required if pain occurs in the legs or groin. This medication is not metabolized by the liver and is excreted through the kidneys, so its impact on liver function is minimal, but kidney function should be closely monitored. It is preferable to avoid this medication during pregnancy or breastfeeding as its safety has not been established. The efficacy and safety of this medication have not been confirmed in children, so it should not be used in pediatric populations. In cases of overdose, hypocalcemia, hypophosphatemia, and hypomagnesemia may occur, so careful monitoring is necessary, and appropriate treatment should be provided if necessary. This medication must not be mixed with calcium-containing solutions or other intravenous medications and should only be administered with normal saline or 5% dextrose solution. After use, the syringe and needle should not be reused and should be disposed of safely, keeping them out of reach of children.
Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illnesses, fatigue, headache, rash, bone pain, weakness, injection site reactions, phlebitis, thrombophlebitis, hypersensitivity reactions, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reactions, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical extra-articular fractures, intertrochanteric femoral fracture, dizziness, optic atrophy, lower motor neuron disease, tremor, unspecified gastrointestinal disorders, benign gastrointestinal tumors, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, hemorrhage in the eye, heart failure, urination disorders, hematuria, skin shedding, acute renal failure, sensory loss
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air from entering and kept at room temperature between 1 degree and 30 degrees Celsius. Storing it this way will help maintain its effectiveness for a long time.
A colorless and transparent solution contained in a colorless and transparent glass prefilled syringe, accompanied by a single-use needle.
3ml x 1 vial
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 3.375mg
Injections · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.